Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise ...

Theratechnologies Inc.’s THTX share price has dipped by 14.84%, which has investors questioning if this is right time to buy.

Ionis Pharma's olezarsen has become the first FDA-approved drug therapy for adults with familial chylomicronaemia syndrome (FCS), an ultra-rare disease that leads to elevated triglyceride levels ...

At ACC, Ionis reported results from the phase 3 BALANCE trial of its olezarsen candidate in patients with FCS, showing that an 80 mg dose given by monthly subcutaneous injection reduced ...

Medscape Medical News, April 10, 2024 ACC 2024 Early Olezarsen Results Show 50% Reduction in Triglycerides A drug targeting mRNA essential for APO C-III production provided a 50% reduction in ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...

Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Alnylam, Ionis, and Sarepta lead the RNA ...